Inventor
BEELEY NIGEL R A
GB33 patents
⚠️ This page may combine multiple inventors who share the name “BEELEY NIGEL R A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ELCELYX THERAPEUTICS INC
10 patentsUS9962344B2May 8, 2018
Chemosensory receptor ligand-based therapies
ELCELYX THERAPEUTICS INC14 citations92
US9481642B2Nov 1, 2016
Biguanide compositions and methods of treating metabolic disorders
ELCELYX THERAPEUTICS INC14 citations92
US9463170B2Oct 11, 2016
Chemosensory receptor ligand-based therapies
ELCELYX THERAPEUTICS INC15 citations92
US9211263B2Dec 15, 2015
Compositions and methods of treating metabolic disorders
ELCELYX THERAPEUTICS INC24 citations92
US10201511B2Feb 12, 2019
Compositions and methods for treating metabolic disorders
ELCELYX THERAPEUTICS INC8 citations84
US10159658B2Dec 25, 2018
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
ELCELYX THERAPEUTICS INC8 citations84
US10154972B2Dec 18, 2018
Biguanide compositions and methods of treating metabolic disorders
ELCELYX THERAPEUTICS INC10 citations84
US10028923B2Jul 24, 2018
Biguanide compositions and methods of treating metabolic disorders
ELCELYX THERAPEUTICS INC9 citations84
US9770422B2Sep 26, 2017
Compositions and methods for treating metabolic disorders
ELCELYX THERAPEUTICS INC7 citations84
US9572784B2Feb 21, 2017
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
ELCELYX THERAPEUTICS INC7 citations84
AMYLIN PHARMACEUTICALS INC
4 patentsUS7928065B2Apr 19, 2011
Methods of treatment using exendin peptides or GLP-1 peptides
AMYLIN PHARMACEUTICALS INC63 citations97
US6703359B1Mar 9, 2004
Inotropic and diuretic effects of exendin and GLP-1
AMYLIN PHARMACEUTICALS INC160 citations97
US7442680B2Oct 28, 2008
Inotropic and diuretic effects of GLP-1 and GLP-1 agonists
AMYLIN PHARMACEUTICALS INC66 citations96
US6936584B1Aug 30, 2005
Mixed amylin activity compounds
AMYLIN PHARMACEUTICALS INC4 citations61
CELLTECH LTD
3 patentsUS5340827AAug 23, 1994
Phenylcarboxamide compounds which have useful pharmaceutical activity
CELLTECH LTD127 citations97
US5569665AOct 29, 1996
Peptidyl derivatives and their use as metalloproteinases inhibitors
CELLTECH LTD21 citations91
US5300501AApr 5, 1994
Peptidyl derivatives
CELLTECH LTD20 citations91
CELLTECH THERAPEUTICS LTD
3 patentsUS5550137AAug 27, 1996
Phenylaminocarbonyl derivatives
CELLTECH THERAPEUTICS LTD64 citations96
US5565562AOct 15, 1996
Triaza macrocycles
CELLTECH THERAPEUTICS LTD31 citations92
US5530128AJun 25, 1996
N-sulphonylamino derivatives of dipetide compounds as metalloproteinase inhibitors
CELLTECH THERAPEUTICS LTD5 citations61
BARON ALAIN D
3 patentsUS8796338B2Aug 5, 2014
Biguanide compositions and methods of treating metabolic disorders
BARON ALAIN D27 citations92
US9050292B2Jun 9, 2015
Chemosensory receptor ligand-based therapies
BARON ALAIN D24 citations90
US9480663B2Nov 1, 2016
Biguanide compositions and methods of treating metabolic disorders
BARON ALAIN D8 citations83
ANJI PHARMA US LLC
3 patentsUS10610500B2Apr 7, 2020
Chemosensory receptor ligand-based therapies
ANJI PHARMA US LLC8 citations83
US10603291B2Mar 31, 2020
Compositions and methods for treating metabolic disorders
ANJI PHARMA US LLC5 citations83
US11065215B2Jul 20, 2021
Biguanide compositions and methods of treating metabolic disorders
ANJI PHARMA US LLC3 citations72